|
|
Article: U.S. Patent Disclosures.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Athersys Inc., of Cleveland, was issued U.S. Patent No. 6,361,972 titled "Compositions and Methods for Non-Targeted Activation of Endogenous Genes" and covering aspects of its RAGE (Random Activation of Gene Expression) technology.
Avigen Inc., of Alameda, Calif., was awarded U.S. Patent No. 6,325,998 covering the use of recombinant adeno-associated virus, free of both wild-type AAV and infectious helper virus, to deliver any therapeutic gene to muscle cells. A second issued patent, U.S. Patent No. 6,335,011, covers methods for delivering genes via AAV to muscle tissue to treat any of the lysosomal storage diseases, including Gaucher's disease and Hurler's ...